STOCK TITAN

Esperion Therape Stock Price, News & Analysis

ESPR Nasdaq

Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.

Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.

News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.

By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.39%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
conferences
Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will participate in a fireside chat at the Bank of America Securities 2023 Health Care Conference on May 11, 2023, at 11:40 AM PDT. Interested parties can register for the live webcast through a provided link.

A live audio broadcast will be available on the investor section of Esperion's website, with a replay set to be accessible about two hours post-event and archived for roughly 90 days.

Esperion is focused on developing medicines for patients with cardiovascular diseases, addressing the urgent need for effective treatments to lower LDL-cholesterol levels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
conferences

FAQ

What is the current stock price of Esperion Therape (ESPR)?

The current stock price of Esperion Therape (ESPR) is $2.69 as of March 16, 2026.

What is the market cap of Esperion Therape (ESPR)?

The market cap of Esperion Therape (ESPR) is approximately 583.3M.

ESPR Rankings

ESPR Stock Data

583.31M
228.77M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR

ESPR RSS Feed